Johnson & Johnson (NYSE:JNJ) VP Sells $13,672,412.88 in Stock

Johnson & Johnson (NYSE:JNJ) VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the transaction, the vice president now directly owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Johnson & Johnson (JNJ) traded up 0.67% on Wednesday, hitting $134.27. The stock had a trading volume of 2,399,705 shares. The company’s 50 day moving average price is $132.93 and its 200 day moving average price is $126.81. Johnson & Johnson has a 52-week low of $109.32 and a 52-week high of $137.08. The firm has a market cap of $360.38 billion, a price-to-earnings ratio of 22.72 and a beta of 0.78.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.04. The firm had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The business’s revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the company earned $1.74 EPS. Analysts expect that Johnson & Johnson will post $7.18 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 2.52%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is 56.76%.

TRADEMARK VIOLATION WARNING: “Johnson & Johnson (NYSE:JNJ) VP Sells $13,672,412.88 in Stock” was first posted by BBNS and is the sole property of of BBNS. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://baseballnewssource.com/markets/insider-selling-johnson-johnson-nysejnj-vp-sells-13672412-88-in-stock-updated-updated-updated/1310457.html.

Several hedge funds have recently made changes to their positions in JNJ. Norges Bank purchased a new stake in Johnson & Johnson during the fourth quarter worth $3,220,322,000. State Street Corp raised its stake in Johnson & Johnson by 4.3% in the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after buying an additional 6,656,371 shares during the period. Asset Management One Co. Ltd. raised its stake in Johnson & Johnson by 1,147.4% in the fourth quarter. Asset Management One Co. Ltd. now owns 4,946,229 shares of the company’s stock worth $569,967,000 after buying an additional 4,549,711 shares during the period. BlackRock Inc. raised its stake in Johnson & Johnson by 2.6% in the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after buying an additional 4,332,612 shares during the period. Finally, Janus Henderson Group PLC raised its stake in Johnson & Johnson by 717.9% in the second quarter. Janus Henderson Group PLC now owns 3,748,008 shares of the company’s stock worth $495,837,000 after buying an additional 3,289,763 shares during the period. Hedge funds and other institutional investors own 66.10% of the company’s stock.

A number of equities research analysts recently issued reports on JNJ shares. J P Morgan Chase & Co upgraded Johnson & Johnson from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $123.64 to $140.00 in a research report on Monday, May 15th. UBS AG reiterated a “buy” rating and issued a $148.00 price objective (up previously from $136.00) on shares of Johnson & Johnson in a research report on Wednesday, July 19th. Alembic Global Advisors downgraded Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research report on Friday, July 21st. Vetr downgraded Johnson & Johnson from a “buy” rating to a “hold” rating and set a $128.82 price objective on the stock. in a research report on Monday, May 15th. Finally, BTIG Research reiterated a “hold” rating on shares of Johnson & Johnson in a research report on Wednesday, April 19th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the stock. Johnson & Johnson presently has an average rating of “Hold” and an average target price of $134.12.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with our FREE daily email newsletter.

 


Latest News

Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury
Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras
Cleveland Indians Acquire Jay Bruce From New York Mets
Cleveland Indians Acquire Jay Bruce From New York Mets
Injury to CC Sabathia Adds to Yankees’ Concerns
Injury to CC Sabathia Adds to Yankees’ Concerns


Leave a Reply

 
© 2006-2017 BBNS.